

Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Application (Vaccine, Monoclonal Antibodies, Blood products, Cell & Gene Therapy Products), Test Type (Endotoxin, Myoplasm, Sterility Test) - Global Forecast to 2026

<https://marketpublishers.com/r/BE9957281F6EN.html>

Date: January 2023

Pages: 242

Price: US\$ 4,950.00 (Single User License)

ID: BE9957281F6EN

Abstracts

The global biologics safety testing market is projected to reach USD 6.8 billion by 2027 from USD 3.6 billion in 2022, at a CAGR of 13.3% during the forecast period. The growth of the global biologics safety testing market is driven by factors such as the strict regulatory scenario implemented for quality control testing for biopharmaceutical production, increase in the number of approved biologics products worldwide, growing use of biologics safety testing reagents and kits for cell culture contamination detection, and increases in R&D spending and government support will significantly boost biologics testing activities.

“By product & service segment, the service segment accounted for the largest share of the Biologics Safety Testing market”

Based on product and service, the biologics safety testing market is segmented into consumables, services, and instruments. In 2021, the services segment accounted for the largest market share. The large share of this segment can be attributed to large biopharmaceutical companies routinely outsource numerous tasks, such as process and product validation, process monitoring and quality control, toxicology, and other preclinical studies.

”By application, the monoclonal antibodies development and manufacturing segment accounted for the largest market share of the Biologics safety testing market “

Based on application, the biologics safety testing market is segmented into monoclonal antibodies development and manufacturing, vaccines development and manufacturing, blood and blood products development and manufacturing, cellular and gene therapy products development and manufacturing, and other applications. In 2021, the monoclonal antibodies development and manufacturing segment accounted for the largest market share. The large share of this segment can be attributed to the growing number of regulatory approvals.

“Asia Pacific: The fastest-growing region in the biologics safety testing market.”

The biologics safety testing market in the Asia Pacific region is projected to register the highest growth during the forecast period. Factors such as growth in the outsourcing industry in the Asia Pacific region, vastly expanding R&D funding by biopharmaceutical companies and government, minimized outsourcing costs, and rising patient population resulting in growing manufacturing of biologics are expected to drive market growth.

“North America accounted for the largest share of the Biologics safety testing market in 2021”

North America accounted for the largest share of the biologics safety testing market in 2021. Rapid growth in the biopharmaceutical industry is the major factor driving the growth of the North American biologics safety testing market. High number of pre-registration and other-phase drugs in the pipeline by pharmaceutical companies and biotechnology/gene therapy/genomics companies and the presence of major market players in this region are also driving the market for biologics safety testing in North America.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

By Respondent— Supply Side- 80%, Demand Side-20%

By Designation— CXOs - 20%, Executives - 25%, Mangers - 55%

By Region— North America - 40%, Europe - 30%, APAC – 20%, LATAM & MEA- 10%

The Biologics Safety Testing market is dominated by a few globally established players such as Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Labcorp (US), SGS SA (Switzerland), WuXi AppTec (China), Sartorius AG (Germany), Associates of Cape Cod, Inc. (US), bioMérieux SA (France), Eurofins Scientific (Luxembourg), FUJIFILM Wako Pure Chemical Corporation (Japan), Almac Group (UK), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany), Pacific BioLabs (US), InvivoGen (US), Microcoat Biotechnologie GmbH (Germany), PromoCell GmbH (Germany), Samsung Biologics (South Korea), GenScript (China), Maravai Lifesciences (US), Accugen Laboratories, Inc. (US) and Nelson Laboratories, LCC (US)

Research Coverage:

The report segments the Biologics Safety Testing market based on region (Asia Pacific, Europe, North America, Latin America and Middle East and Africa), product and service (consumables, services, and instruments), application (monoclonal antibodies development and manufacturing, vaccines development and manufacturing, blood and blood products development and manufacturing, cellular and gene therapy products development and manufacturing, and other applications.), and test types (endotoxin tests, sterility tests, mycoplasma tests, bioburden tests, virus safety tests, residual host-cell proteins and DNA detection tests, and other biologics safety tests). The report also provides a comprehensive review of market drivers, opportunities, challenges and restraints in the Biologics Safety Testing market.

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the Biologics Safety Testing market and provides them information on key market drivers, restraints, challenges, and opportunities.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS AND EXCLUSIONS

1.2.2 MARKETS COVERED

FIGURE 1 BIOLOGICS SAFETY TESTING MARKET SEGMENTATION

1.2.3 YEARS CONSIDERED

1.3 CURRENCY CONSIDERED

1.4 LIMITATIONS

1.5 STAKEHOLDERS

1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH APPROACH

FIGURE 2 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.2 PRIMARY DATA

FIGURE 3 BREAKDOWN OF PRIMARIES: BIOLOGICS SAFETY TESTING MARKET

2.1.3 DATA TRIANGULATION APPROACH

2.2 DATA TRIANGULATION

FIGURE 4 DATA TRIANGULATION METHODOLOGY

2.3 MARKET ESTIMATION METHODOLOGY

FIGURE 5 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION

FIGURE 6 MARKET SIZE ESTIMATION: SEGMENTAL ANALYSIS-BASED ESTIMATION

FIGURE 7 BIOLOGICS SAFETY TESTING MARKET: FINAL CAGR PROJECTION (2022?2027)

FIGURE 8 BIOLOGICS SAFETY TESTING: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

2.4 INDUSTRY INSIGHTS

2.5 RESEARCH ASSUMPTIONS

2.6 RECESSION IMPACT

TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024?2027 (% GROWTH)

3 EXECUTIVE SUMMARY

FIGURE 9 BIOLOGICS SAFETY TESTING MARKET SHARE, BY PRODUCT & SERVICE (2021)

FIGURE 10 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)

FIGURE 11 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION)

FIGURE 12 BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES

4 PREMIUM INSIGHTS

4.1 BIOLOGICS SAFETY TESTING MARKET OVERVIEW

FIGURE 13 RISING DEVELOPMENT OF BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET

4.2 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION AND COUNTRY (2021)

FIGURE 14 MONOCLONAL ANTIBODIES MANUFACTURING SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021

4.3 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE

FIGURE 15 RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS SEGMENT TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 MARKET DYNAMICS

FIGURE 16 BIOLOGICS SAFETY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.1.1 DRIVERS

5.1.1.1 Growing development of biosimilars and biologics

TABLE 2 LIST OF BIOLOGICAL LICENSE APPLICATION APPROVALS IN US, 2021

TABLE 3 LIST OF BIOLOGICS APPROVED BY US FDA (2021)

5.1.1.2 Growing concerns over cell culture contamination

5.1.1.3 Rising investments in biopharmaceutical R&D

TABLE 4 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2020 VS. 2026 (USD BILLION)

FIGURE 17 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE,

2017–2024

5.1.2 RESTRAINTS

5.1.2.1 Shortage of skilled professionals

5.1.3 OPPORTUNITIES

5.1.3.1 Emerging markets

5.1.3.2 Increasing outsourcing of biopharmaceutical activities to CROs

5.1.4 CHALLENGES

5.1.4.1 High cost of biologics

5.2 PRICING ANALYSIS

TABLE 5 AVERAGE SELLING PRICE OF BIOLOGICS SAFETY TESTING PRODUCTS

(2020-2021)

5.2.1 PRICING TREND ANALYSIS

5.3 VALUE CHAIN ANALYSIS

FIGURE 18 BIOLOGICS SAFETY TESTING MARKET: VALUE CHAIN ANALYSIS

5.4 ECOSYSTEM ANALYSIS

FIGURE 19 BIOLOGICS SAFETY TESTING MARKET: ECOSYSTEM ANALYSIS

5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

FIGURE 20 REVENUE SHIFT FOR BIOLOGICS SAFETY TESTING PROVIDERS

5.6 PATENT ANALYSIS

FIGURE 21 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR BIOLOGICS SAFETY PATENTS (JANUARY 2012?NOVEMBER 2022)

TABLE 6 BIOLOGICS SAFETY TESTING MARKET: INDICATIVE LIST OF PATENTS

5.7 REGULATORY ANALYSIS

5.7.1 US

5.7.2 EUROPE

5.7.3 ASIA PACIFIC

5.7.4 LATIN AMERICA

5.7.5 MIDDLE EAST AND AFRICA

5.7.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT

AGENCIES, AND OTHER ORGANIZATIONS

5.8 PORTER'S FIVE FORCES ANALYSIS

TABLE 11 BIOLOGICS SAFETY TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS

5.8.1 THREAT OF NEW ENTRANTS

5.8.2 THREAT OF SUBSTITUTES

5.8.3 BARGAINING POWER OF BUYERS

5.8.4 BARGAINING POWER OF SUPPLIERS

5.8.5 INTENSITY OF COMPETITIVE RIVALRY

5.9 KEY CONFERENCES AND EVENTS IN 2022–2023

TABLE 12 BIOLOGICS SAFETY TESTING MARKET: CONFERENCES AND EVENTS

5.10 KEY STAKEHOLDERS AND BUYING CRITERIA

FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCTS & SERVICES

FIGURE 23 BUYING CRITERIA FOR BIOLOGICS SAFETY TESTING PRODUCTS & SERVICES

6 BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE

6.1 INTRODUCTION

TABLE 13 BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

6.2 SERVICES

6.2.1 INCREASING OUTSOURCING OF SERVICES TO CROSS TO DRIVE MARKET

TABLE 14 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 15 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 16 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 17 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

6.3 CONSUMABLES

6.3.1 RECURRENT PURCHASE OF ASSAYS, KITS, AND REAGENTS TO DRIVE MARKET

TABLE 18 BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 19 NORTH AMERICA: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 20 EUROPE: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 21 ASIA PACIFIC: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

6.4 INSTRUMENTS

6.4.1 LONGER SHELF LIFE OF INSTRUMENTS TO RESTRAIN MARKET

TABLE 22 BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 23 NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 24 EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 25 ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE

7.1 INTRODUCTION

TABLE 26 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

7.2 RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS

7.2.1 GROWING USE OF RDNA IN VARIOUS MANUFACTURING STAGES TO DRIVE MARKET

TABLE 27 RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 28 NORTH AMERICA: RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 29 EUROPE: RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 30 ASIA PACIFIC: RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.3 MYCOPLASMA TESTS

7.3.1 GROWING CONCERNS OVER CELL CULTURE CONTAMINATION TO DRIVE MARKET

TABLE 31 MYCOPLASMA TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 32 NORTH AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 33 EUROPE: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 34 ASIA PACIFIC: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.4 STERILITY TESTS

7.4.1 MANDATORY TESTING CONDUCTED FOR DRUG DEVELOPMENT & PRODUCTION TO DRIVE MARKET

TABLE 35 STERILITY TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 36 NORTH AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 37 EUROPE: STERILITY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 38 ASIA PACIFIC: STERILITY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.5 ENDOTOXIN TESTS

7.5.1 RISING DEMAND FOR LAL TESTING TO SUPPORT MARKET GROWTH

TABLE 39 ENDOTOXIN TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 40 NORTH AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 41 EUROPE: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 42 ASIA PACIFIC: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.6 VIRUS SAFETY TESTS

7.6.1 RISING UPTAKE IN VACCINE DEVELOPMENT AND CELL & GENE THERAPY TO SUPPORT MARKET

TABLE 43 VIRUS SAFETY TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 44 NORTH AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 45 EUROPE: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 46 ASIA PACIFIC: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7.7 BIOBURDEN TESTS

7.7.1 GROWING CONCERNS FOR DRUG SAFETY STANDARDS TO PROPEL MARKET

TABLE 47 BIOBURDEN TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 48 NORTH AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 49 EUROPE: BIOBURDEN TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 50 ASIA PACIFIC: BIOBURDEN TESTS MARKET, BY COUNTRY, 2020–2027
(USD MILLION)

7.8 OTHER BIOLOGICS SAFETY TESTS

TABLE 51 OTHER BIOLOGICS SAFETY TESTS MARKET, BY REGION, 2020–2027
(USD MILLION)

TABLE 52 NORTH AMERICA: OTHER BIOLOGICS SAFETY TESTS MARKET, BY
COUNTRY, 2020–2027 (USD MILLION)

TABLE 53 EUROPE: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)

TABLE 54 ASIA PACIFIC: OTHER BIOLOGICS SAFETY TESTS MARKET, BY
COUNTRY, 2020–2027 (USD MILLION)

8 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION

8.1 INTRODUCTION

TABLE 55 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027
(USD MILLION)

8.2 MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING

8.2.1 RISING APPROVALS FOR BIOSIMILAR MABS TO DRIVE MARKET

TABLE 56 BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL
ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY REGION, 2020–2027
(USD MILLION)

TABLE 57 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR
MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY
COUNTRY, 2020–2027 (USD MILLION)

TABLE 58 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL
ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027
(USD MILLION)

TABLE 59 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR
MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY
COUNTRY, 2020–2027 (USD MILLION)

8.3 VACCINE DEVELOPMENT AND MANUFACTURING

8.3.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET

TABLE 60 BIOLOGICS SAFETY TESTING MARKET FOR VACCINE DEVELOPMENT
AND MANUFACTURING, BY REGION, 2020–2027 (USD MILLION)

TABLE 61 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR
VACCINE DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027
(USD MILLION)

TABLE 62 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR VACCINE

DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 63 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR VACCINE

DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)

8.4 CELLULAR & GENE THERAPY PRODUCT DEVELOPMENT AND
MANUFACTURING

8.4.1 RISING ADOPTION OF CELLULAR IMMUNOTHERAPIES FOR CANCER
TREATMENT TO DRIVE MARKET

TABLE 64 BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE
THERAPY PRODUCT DEVELOPMENT AND MANUFACTURING, BY REGION,
2020–2027 (USD MILLION)

TABLE 65 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR
CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND
MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 66 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR &
GENE THERAPY PRODUCT DEVELOPMENT AND MANUFACTURING, BY
COUNTRY, 2020–2027 (USD MILLION)

TABLE 67 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR
& GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY
COUNTRY, 2020–2027 (USD MILLION)

8.5 BLOOD & BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING

8.5.1 RISING UPTAKE OF STERILITY TESTS TO SUPPORT MARKET GROWTH

TABLE 68 BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD
PRODUCT DEVELOPMENT AND MANUFACTURING, BY REGION, 2020–2027 (USD
MILLION)

TABLE 69 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD
& BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING, BY COUNTRY,
2020–2027 (USD MILLION)

TABLE 70 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD &
BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING, BY COUNTRY,
2020–2027 (USD MILLION)

TABLE 71 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD &
BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING, BY COUNTRY,
2020–2027 (USD MILLION)

8.6 OTHER APPLICATIONS

TABLE 72 BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION)

TABLE 73 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR OTHER
APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 74 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR OTHER

APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 75 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

9 BIOLOGICS SAFETY TESTING MARKET, BY END USER

9.1 INTRODUCTION

TABLE 76 BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES

9.2.1 GROWING R&D EXPENDITURE FOR DRUG DEVELOPMENT TO DRIVE MARKET

FIGURE 24 PHARMACEUTICAL R&D SPENDING (2014–2028)

TABLE 77 BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)

TABLE 78 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 79 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 80 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)

9.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CROS AND CDMOS)

9.3.1 ABILITY TO PROVIDE SPECIALIZED MANUFACTURING AND SAFETY TESTING TECHNOLOGIES TO DRIVE MARKET

TABLE 81 BIOLOGICS SAFETY TESTING MARKET FOR CROS AND CDMOS, BY REGION, 2020–2027 (USD MILLION)

TABLE 82 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CRS AND CDMOS, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 83 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CROS AND CDMOS, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 84 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CROS AND CDMOS, BY COUNTRY, 2020–2027 (USD MILLION)

9.4 ACADEMIC & RESEARCH INSTITUTES

9.4.1 AVAILABILITY OF ADVANCED EQUIPMENT AND SPECIALIZED R&D

PERSONNEL TO SUPPORT MARKET GROWTH

TABLE 85 BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)

TABLE 86 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 87 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 88 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)

10 BIOLOGICS SAFETY TESTING MARKET, BY REGION

10.1 INTRODUCTION

TABLE 89 BIOLOGICS SAFETY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)

10.2 NORTH AMERICA

FIGURE 25 BIOLOGICS SAFETY TESTING MARKET: NORTH AMERICA MARKET SNAPSHOT

TABLE 90 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 91 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 92 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 93 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 94 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.2.1 US

10.2.1.1 High investments in biopharmaceutical R&D to drive market

TABLE 95 US: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE,

2020–2027 (USD MILLION)

TABLE 96 US: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE,

2020–2027 (USD MILLION)

TABLE 97 US: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION,

2020–2027 (USD MILLION)

TABLE 98 US: BIOLOGICS SAFETY TESTING MARKET, BY END USER,

2020–2027 (USD MILLION)

10.2.2 CANADA

10.2.2.1 Presence of R&D clusters and growing life sciences research to drive market

TABLE 99 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 100 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE,

2020–2027 (USD MILLION)

TABLE 101 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION,

2020–2027 (USD MILLION)

TABLE 102 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY END USER,

2020–2027 (USD MILLION)

10.2.3 NORTH AMERICA: RECESSION IMPACT

10.3 EUROPE

TABLE 103 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY,

2020–2027 (USD MILLION)

TABLE 104 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 105 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 106 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 107 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.1 GERMANY

10.3.1.1 Favorable R&D funding by federal and state governments to propel market

TABLE 108 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 109 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 110 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 111 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.2 UK

10.3.2.1 Growing focus on investments in vaccine manufacturing to drive market

TABLE 112 UK: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 113 UK: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 114 UK: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 115 UK: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.3 FRANCE

10.3.3.1 Government initiatives to strengthen R&D activities to support market growth

TABLE 116 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 117 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 118 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 119 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.4 ITALY

10.3.4.1 Favorable government support for establishment of biotech startups to propel market

TABLE 120 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 121 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 122 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 123 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.5 SPAIN

10.3.5.1 Increasing biologics production and outsourcing testing services to support market growth

TABLE 124 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 125 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 126 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 127 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.6 REST OF EUROPE

TABLE 128 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 129 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 130 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 131 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.7 EUROPE: RECESSION IMPACT

10.4 ASIA PACIFIC

FIGURE 26 BIOLOGICS SAFETY TESTING MARKET: ASIA PACIFIC MARKET SNAPSHOT

TABLE 132 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 133 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 134 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 135 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 136 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY END USERS, 2020–2027 (USD MILLION)

10.4.1 CHINA

10.4.1.1 Rising approvals for drug applications and high R&D innovation to drive market

TABLE 137 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 138 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 139 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 140 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.4.2 JAPAN

10.4.2.1 Rising investments for establishment of cell & gene therapy facilities to propel market

TABLE 141 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 142 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 143 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 144 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.4.3 INDIA

10.4.3.1 High demand for export of pharmaceuticals and vaccines to drive market

TABLE 145 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 146 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 147 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 148 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.4.4 REST OF ASIA PACIFIC

TABLE 149 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 150 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 151 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 152 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.4.5 ASIA PACIFIC: RECESSION IMPACT

10.5 LATIN AMERICA

10.5.1 GROWING APPROVAL OF BIOSIMILARS TO SUPPORT MARKET GROWTH

TABLE 153 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 154 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 155 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 156 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.5.2 LATIN AMERICA: RECESSION IMPACT

10.6 MIDDLE EAST & AFRICA

10.6.1 RISING FOCUS ON DRUG DISCOVERY AND DEVELOPMENT TO SUPPORT MARKET GROWTH

TABLE 157 MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 158 MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)

TABLE 159 MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 160 MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

11.2 RIGHT-TO-WIN STRATEGIES ADOPTED BY KEY PLAYERS

FIGURE 27 BIOLOGICS SAFETY TESTING MARKET: KEY PLAYER STRATEGIES (2019–2022)

11.3 MARKET SHARE ANALYSIS

FIGURE 28 BIOLOGICS SAFETY TESTING MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2021 (TOP EIGHT)

TABLE 161 BIOLOGICS SAFETY TESTING MARKET: INTENSITY OF COMPETITIVE RIVALRY

11.4 REVENUE SHARE ANALYSIS OF KEY PLAYERS

FIGURE 29 BIOLOGICS SAFETY TESTING MARKET: REVENUE SHARE ANALYSIS OF KEY PLAYERS (TOP EIGHT)

11.5 COMPANY EVALUATION MATRIX

11.5.1 STARS

11.5.2 EMERGING LEADERS

11.5.3 PERVASIVE PLAYERS

11.5.4 PARTICIPANTS

FIGURE 30 BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX, 2021

11.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS

11.6.1 PROGRESSIVE COMPANIES

11.6.2 STARTING BLOCKS

11.6.3 DYNAMIC COMPANIES

11.6.4 RESPONSIVE COMPANIES

FIGURE 31 BIOLOGICS SAFETY TESTING: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS (2021)

11.7 COMPETITIVE BENCHMARKING

11.7.1 COMPANY PRODUCT FOOTPRINT

TABLE 162 BIOLOGICS SAFETY TESTING MARKET: PRODUCT PORTFOLIO ANALYSIS

11.7.2 COMPANY TEST TYPE FOOTPRINT

TABLE 163 BIOLOGICS SAFETY TESTING MARKET: TEST TYPE ANALYSIS

11.7.3 COMPANY GEOGRAPHIC FOOTPRINT

TABLE 164 BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHIC ANALYSIS

11.7.4 OVERALL COMPANY FOOTPRINT (25 COMPANIES)

TABLE 165 BIOLOGICS SAFETY TESTING MARKET: COMPANY FOOTPRINT

11.7.4.1 COMPETITIVE BENCHMARKING FOR STARTUPS

TABLE 166 BIOLOGICS SAFETY TESTING MARKET: KEY STARTUPS

TABLE 167 BIOLOGICS SAFETY TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS

11.8 COMPETITIVE SCENARIO

11.8.1 BIOLOGICS SAFETY TESTING MARKET: PRODUCT LAUNCHES (JANUARY 2019?DECEMBER 2022)

11.8.2 BIOLOGICS SAFETY TESTING MARKET: DEALS (JANUARY 2019?DECEMBER 2022)

11.8.3 BIOLOGICS SAFETY TESTING MARKET: OTHER DEVELOPMENTS (JANUARY 2019?DECEMBER 2022)

12 COMPANY PROFILES

12.1 KEY PLAYERS

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

12.1.1 CHARLES RIVER LABORATORIES

TABLE 168 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW

FIGURE 32 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2021)

12.1.2 LONZA

TABLE 169 LONZA: BUSINESS OVERVIEW

FIGURE 33 LONZA: COMPANY SNAPSHOT (2021)

12.1.3 THERMO FISHER SCIENTIFIC, INC.

TABLE 170 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW

FIGURE 34 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)

12.1.4 MERCK KGAA

TABLE 171 MERCK KGAA: BUSINESS OVERVIEW

FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2021)

12.1.5 LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)

FIGURE 36 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)

12.1.6 SGS SA

TABLE 173 SGS SA: BUSINESS OVERVIEW

FIGURE 37 SGS SA: COMPANY SNAPSHOT (2021)

12.1.7 EUROFINS SCIENTIFIC

TABLE 174 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW

FIGURE 38 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)

12.1.8 WUXI APPTec

TABLE 175 WUXI APPTec: BUSINESS OVERVIEW

FIGURE 39 WUXI APPTec: COMPANY SNAPSHOT (2021)

12.1.9 ASSOCIATES OF CAPE COD, INC.

TABLE 176 ASSOCIATES OF CAPE COD, INC.: BUSINESS OVERVIEW

12.1.10 BIOM?RIEUX SA

TABLE 177 BIOM?RIEUX SA: BUSINESS OVERVIEW

FIGURE 40 BIOM?RIEUX SA: COMPANY SNAPSHOT (2021)

12.1.11 SAMSUNG BIOLOGICS

TABLE 178 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW

FIGURE 41 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2021)

12.1.12 GENSCRIPT

TABLE 179 GENSCRIPT: BUSINESS OVERVIEW

FIGURE 42 GENSCRIPT: COMPANY SNAPSHOT (2021)

12.1.13 SARTORIUS AG

TABLE 180 SARTORIUS AG: BUSINESS OVERVIEW

FIGURE 43 SARTORIUS AG: COMPANY SNAPSHOT (2021)

12.1.14 F. HOFFMANN-LA ROCHE LTD.

TABLE 181 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)

12.1.15 PACIFIC BIOLABS

TABLE 182 PACIFIC BIOLABS: BUSINESS OVERVIEW

12.1.16 NELSON LABORATORIES, LLC (PART OF SOTERA HEALTH)

TABLE 183 NELSON LABORATORIES: BUSINESS OVERVIEW

12.1.17 AGILENT TECHNOLOGIES, INC.

TABLE 184 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW

FIGURE 45 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021)

12.1.18 MARAVAI LIFESCIENCES

TABLE 185 MARAVAI LIFESCIENCES: BUSINESS OVERVIEW

FIGURE 46 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2021)

12.2 OTHER PLAYERS

12.2.1 QIAGEN

12.2.2 BIO-RAD LABORATORIES, INC.

12.2.3 MICROCOAT BIOTECHNOLOGIE GMBH

12.2.4 INVIVOGEN

12.2.5 PROMOCCELL GMBH

12.2.6 ACCUGEN LABORATORIES, INC.

12.2.7 FUJIFILM WAKO PURE CHEMICAL CORPORATION

12.2.8 ALMAC GROUP

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

13.1 DISCUSSION GUIDE

13.2 KNOWLEDGESTORE: MARKETSDMARKETS' SUBSCRIPTION PORTAL

13.3 CUSTOMIZATION OPTIONS

13.4 RELATED REPORTS

13.5 AUTHOR DETAILS

I would like to order

Product name: Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Application (Vaccine, Monoclonal Antibodies, Blood products, Cell & Gene Therapy Products), Test Type (Endotoxin, Myoplasm, Sterility Test) - Global Forecast to 2026

Product link: <https://marketpublishers.com/r/BE9957281F6EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BE9957281F6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970